301 related articles for article (PubMed ID: 22702508)
1. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial.
Nair P; Gaga M; Zervas E; Alagha K; Hargreave FE; O'Byrne PM; Stryszak P; Gann L; Sadeh J; Chanez P;
Clin Exp Allergy; 2012 Jul; 42(7):1097-103. PubMed ID: 22702508
[TBL] [Abstract][Full Text] [Related]
2. The effects of a CXCR1/CXCR2 antagonist on neutrophil migration in mild atopic asthmatic subjects.
Todd CM; Salter BM; Murphy DM; Watson RM; Howie KJ; Milot J; Sadeh J; Boulet LP; O'Byrne PM; Gauvreau GM
Pulm Pharmacol Ther; 2016 Dec; 41():34-39. PubMed ID: 27640067
[TBL] [Abstract][Full Text] [Related]
3. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects.
Holz O; Khalilieh S; Ludwig-Sengpiel A; Watz H; Stryszak P; Soni P; Tsai M; Sadeh J; Magnussen H
Eur Respir J; 2010 Mar; 35(3):564-70. PubMed ID: 19643947
[TBL] [Abstract][Full Text] [Related]
4. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.
Rennard SI; Dale DC; Donohue JF; Kanniess F; Magnussen H; Sutherland ER; Watz H; Lu S; Stryszak P; Rosenberg E; Staudinger H
Am J Respir Crit Care Med; 2015 May; 191(9):1001-11. PubMed ID: 25695403
[TBL] [Abstract][Full Text] [Related]
5. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans.
Lazaar AL; Sweeney LE; MacDonald AJ; Alexis NE; Chen C; Tal-Singer R
Br J Clin Pharmacol; 2011 Aug; 72(2):282-93. PubMed ID: 21426372
[TBL] [Abstract][Full Text] [Related]
6. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis.
De Soyza A; Pavord I; Elborn JS; Smith D; Wray H; Puu M; Larsson B; Stockley R
Eur Respir J; 2015 Oct; 46(4):1021-32. PubMed ID: 26341987
[TBL] [Abstract][Full Text] [Related]
7. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.
Kirsten AM; Förster K; Radeczky E; Linnhoff A; Balint B; Watz H; Wray H; Salkeld L; Cullberg M; Larsson B
Pulm Pharmacol Ther; 2015 Apr; 31():36-41. PubMed ID: 25681277
[TBL] [Abstract][Full Text] [Related]
8. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
[TBL] [Abstract][Full Text] [Related]
9. The effects of the CXCR2 antagonist, MK-7123, on bone marrow functions in healthy subjects.
Hastrup N; Khalilieh S; Dale DC; Hanson LG; Magnusson P; Tzontcheva A; Tseng J; Huyck S; Rosenberg E; Krogsgaard K
Cytokine; 2015 Apr; 72(2):197-203. PubMed ID: 25661195
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist.
Leaker BR; Barnes PJ; O'Connor B
Respir Res; 2013 Dec; 14(1):137. PubMed ID: 24341382
[TBL] [Abstract][Full Text] [Related]
11. Loss of control of asthma following inhaled corticosteroid withdrawal is associated with increased sputum interleukin-8 and neutrophils.
Maneechotesuwan K; Essilfie-Quaye S; Kharitonov SA; Adcock IM; Barnes PJ
Chest; 2007 Jul; 132(1):98-105. PubMed ID: 17550933
[TBL] [Abstract][Full Text] [Related]
12. Airway inflammation and cellular stress in noneosinophilic atopic asthma.
Tsoumakidou M; Papadopouli E; Tzanakis N; Siafakas NM
Chest; 2006 May; 129(5):1194-202. PubMed ID: 16685009
[TBL] [Abstract][Full Text] [Related]
13. Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30 days with MK-7123, a selective CXCR2 antagonist.
Seiberling M; Kamtchoua T; Stryszak P; Ma X; Langdon RB; Khalilieh S
Int Immunopharmacol; 2013 Oct; 17(2):178-83. PubMed ID: 23791619
[TBL] [Abstract][Full Text] [Related]
14. The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.
Jurcevic S; Humfrey C; Uddin M; Warrington S; Larsson B; Keen C
Br J Clin Pharmacol; 2015 Dec; 80(6):1324-36. PubMed ID: 26182832
[TBL] [Abstract][Full Text] [Related]
15. Administration of a CXC Chemokine Receptor 2 (CXCR2) Antagonist, SCH527123, Together with Oseltamivir Suppresses NETosis and Protects Mice from Lethal Influenza and Piglets from Swine-Influenza Infection.
Ashar HK; Pulavendran S; Rudd JM; Maram P; Achanta M; Chow VTK; Malayer JR; Snider TA; Teluguakula N
Am J Pathol; 2021 Apr; 191(4):669-685. PubMed ID: 33453177
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
[TBL] [Abstract][Full Text] [Related]
17. Mepolizumab and exacerbations of refractory eosinophilic asthma.
Haldar P; Brightling CE; Hargadon B; Gupta S; Monteiro W; Sousa A; Marshall RP; Bradding P; Green RH; Wardlaw AJ; Pavord ID
N Engl J Med; 2009 Mar; 360(10):973-84. PubMed ID: 19264686
[TBL] [Abstract][Full Text] [Related]
18. Clarithromycin targets neutrophilic airway inflammation in refractory asthma.
Simpson JL; Powell H; Boyle MJ; Scott RJ; Gibson PG
Am J Respir Crit Care Med; 2008 Jan; 177(2):148-55. PubMed ID: 17947611
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
[TBL] [Abstract][Full Text] [Related]
20. Downmodulation of CXCL8/IL-8 receptors on neutrophils after recruitment in the airways.
Pignatti P; Moscato G; Casarini S; Delmastro M; Poppa M; Brunetti G; Pisati P; Balbi B
J Allergy Clin Immunol; 2005 Jan; 115(1):88-94. PubMed ID: 15637552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]